1 / 6

What are the important and common adverse events observed with BRAF inhibitors?

What are the important and common adverse events observed with BRAF inhibitors?. How should they be managed? Are there significant differences between the two approved BRAF inhibitors d abrafenib and v emurafenib ?. Vemurafenib : Grade 3/4 adverse r eactions in ≥2% of patients (BRIM2).

elu
Télécharger la présentation

What are the important and common adverse events observed with BRAF inhibitors?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. What are the important and common adverse events observed with BRAF inhibitors? How should they be managed? Are there significant differences between the two approved BRAF inhibitors dabrafenib and vemurafenib?

  2. Vemurafenib: Grade 3/4 adverse reactions in ≥2% of patients (BRIM2) No dose modification or interruption was required Vemurafenib Prescribing Information, Genentech, Inc.; 2011 Sosman et al, N Engl J Med 2012; 366: 707–714

  3. Dabrafenib: Treatment-related AEs in ≥5% of patients (BREAK3) Photosensitivity: dabrafenib (3%), DTIC (5%). Photosensitivity: dabrafenib (3%), DTIC (5%). Hauschild et al, ASCO 2012; LBA8500 Hauschild et al, Lancet 2012; 380: 358–65

  4. BRAF+MEK treatment-related AEs ≥ 20%(all grades) Long et al, ESMO 2012; LBA27 Flaherty et al, N Engl J Med 2012; 367: 1694–703

  5. BRAFi + MEKiassociated AEs (Part C) Long et al, ESMO 2012; LBA27 Flaherty et al, N Engl J Med 2012; 367: 1694–703

  6. Toxicities of BRAF inhibitors? The overall side effect profiles and efficacy of vemurafenib and dabrafenib seen similar • Although fewer squamous cancers appear with dabrafenib, albeit with more fevers The combination of BRAF + MEK clearly results in less skin toxicity but a slightly higher rate of febrile reactions

More Related